Takeda Pharmaceutical (BOVESPA:TAKP34) - Stock Price, News & Analysis

TAKP34 Stock Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

About the company

TAKP34 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	1/6
Financial Health	2/6
Dividends	3/6

Rewards

Trading at 48.2% below our estimate of its fair value

Earnings are forecast to grow 20.92% per year

Risk Analysis

Dividend of 4.55% is not well covered by earnings or cash flows

Interest payments are not well covered by earnings

Large one-off items impacting financial results

Profit margins (3.4%) are lower than last year (7.9%)

Takeda Pharmaceutical Company Limited Competitors

Hypera

BOVESPA:HYPE3

R$19.0b

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹3.6t

Chugai Pharmaceutical

TSE:4519

JP¥8.1t

Jiangsu Hengrui Medicine

SHSE:600276

CN¥295.5b

Price History & Performance

Summary of all time highs, changes and price drops for Takeda Pharmaceutical
Historical stock prices
Current Share Price	JP¥66.46
52 Week High	JP¥92.00
52 Week Low	JP¥66.46
Beta	0.54
1 Month Change	-2.92%
3 Month Change	-5.90%
1 Year Change	-20.76%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-5.06%

Recent updates

Shareholder Returns

	TAKP34	BR Pharmaceuticals	BR Market
7D	-1.6%	0.2%	-1.1%
1Y	-20.8%	-14.1%	10.3%

Return vs Industry: TAKP34 underperformed the BR Pharmaceuticals industry which returned -12.5% over the past year.

Return vs Market: TAKP34 underperformed the BR Market which returned 10.8% over the past year.

Price Volatility

Is TAKP34's price volatile compared to industry and market?
TAKP34 volatility
TAKP34 Average Weekly Movement	2.5%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	4.8%
10% most volatile stocks in BR Market	9.0%
10% least volatile stocks in BR Market	2.2%

Stable Share Price: TAKP34 has not had significant price volatility in the past 3 months.

Volatility Over Time: TAKP34's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1781	49,095	Christophe Weber	www.takeda.com

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands.

Takeda Pharmaceutical Company Limited Fundamentals Summary

How do Takeda Pharmaceutical's earnings and revenue compare to its market cap?
TAKP34 fundamental statistics
Market cap	R$214.48b
Earnings (TTM)	R$4.77b
Revenue (TTM)	R$141.16b

45.0x

P/E Ratio

1.5x

P/S Ratio

Is TAKP34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TAKP34 income statement (TTM)
Revenue	JP¥4.26t
Cost of Revenue	JP¥1.43t
Gross Profit	JP¥2.84t
Other Expenses	JP¥2.69t
Earnings	JP¥144.07b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 31, 2024

Earnings per share (EPS)	91.82
Gross Margin	66.54%
Net Profit Margin	3.38%
Debt/Equity Ratio	66.6%

How did TAKP34 perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

204%

Payout Ratio

TAKP34 Stock Overview

Rewards

Risk Analysis

Takeda Pharmaceutical Company Limited Competitors

BOVESPA:HYPE3

R$19.0b

NSEI:SUNPHARMA

₹3.6t

TSE:4519

JP¥8.1t

SHSE:600276

CN¥295.5b

Price History & Performance

Recent News & Updates

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Recent updates

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Pharmaceutical Company Limited Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura

Takeda’S Phase 3 Aurora Study Provides Evidence of Maribavir’S Clinically Meaningful and Durable Effect in Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Takeda's Qdenga(R) Dengue Tetravalent Vaccine [Live, Attenuated]) Approves for Use in European Union

Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration Accept and Grant Priority Review of the Biologics License Application for TAK-003

Takeda Announces Phase 3 Trial of Iclusig (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, Setting with No Targeted Treatments Approved in the US

Takeda Announces European Commission Approves LIVTENCITY (Maribavir) for Treatment of Adults with Post-Transplant Cytomegalovirus Infection and/or Disease that are Refractory (with or without Resistance) to One or More Prior Therapies

Takeda Pharmaceutical Company Limited to Report Q3, 2023 Results on Feb 02, 2023

Takeda Pharmaceutical Company Limited Revised Earnings Guidance for the Full Year of 2022

Shareholder Returns

Price Volatility